Natera (NASDAQ:NTRA) Reaches New 52-Week High – Time to Buy?

Natera, Inc. (NASDAQ:NTRA)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $133.88 and last traded at $133.32, with a volume of 722470 shares trading hands. The stock had previously closed at $130.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NTRA shares. Stephens restated an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. Piper Sandler restated an “overweight” rating and set a $150.00 price target on shares of Natera in a research note on Friday, September 13th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group boosted their price objective on Natera from $145.00 to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Finally, TD Cowen boosted their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $125.69.

Natera Trading Up 2.9 %

The company has a market capitalization of $16.59 billion, a PE ratio of -54.74 and a beta of 1.53. The stock has a fifty day moving average of $124.35 and a 200 day moving average of $113.75. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.97) EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 256 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now owns 111,891 shares in the company, valued at approximately $13,434,752.37. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Natera news, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the transaction, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the transaction, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,164 shares of company stock valued at $6,157,291 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after acquiring an additional 72,848 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Natera by 6.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after buying an additional 148,917 shares in the last quarter. Duquesne Family Office LLC grew its position in shares of Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after buying an additional 45,500 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after buying an additional 246,246 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.